(R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-indazol-1-yl)piperidin-1-yl)prop-2-en-1-one

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-indazol-1-yl)piperidin-1-yl)prop-2-en-1-one
• 英文别名: 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)indazol-1-yl]piperidin-1-yl]prop-2-en-1-one
• 化学式: C₂₇H₂₆N₄O₂
• 分子量: 438.5
• InChiKey: UKSCBKJHLGMORO-HXUWFJFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  33
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  73.4
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] BRUTON'S TYROSINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE LA TYROSINE KINASE DE BRUTON
  申请人：SUNNYLIFE PHARMA INC

  公开号：WO2017127371A1

  公开（公告）日：2017-07-27

  Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I).

  Bruton's酪氨酸激酶（Btk）抑制剂具有以下化学式（I）。
• Bruton's tyrosine kinase inhibitors
  申请人：Zibo Biopolar Changsheng Pharmaceutical Co. Ltd.

  公开号：US10662187B2

  公开（公告）日：2020-05-26

  Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):

  布鲁顿酪氨酸激酶（Btk）抑制剂具有下式（I）：
• FORMULATIONS COMPRISING IBRUTINIB
  申请人：PRINCIPIA BIOPHARMA INC.

  公开号：US20150140085A1

  公开（公告）日：2015-05-21

  Oral pharmaceutical formulations of ibrutinib and/or a pharmaceutically acceptable salt thereof, methods for their administration, process of their production, and use of these formulations for the treatment of diseases treatable by ibrutinib such as cancer, inflammatory diseases, and autoimmune diseases.
• BRUTON'S TYROSINE KINASE INHIBITORS
  申请人：Zibo Biopolar Changsheng Pharmaceutical Co. Ltd.

  公开号：US20190276453A1

  公开（公告）日：2019-09-12

  Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):
• [EN] FORMULATIONS COMPRISING IBRUTINIB<br/>[FR] FORMULATIONS COMPRENANT DE L'IBRUTINIB
  申请人：PRINCIPIA BIOPHARMA INC

  公开号：WO2014004707A1

  公开（公告）日：2014-01-03

  Oral pharmaceutical formulations of ibrutinib and/or a pharmaceutically acceptable salt thereof, methods for their administration, process of their production, and use of these formulations for the treatment of diseases treatable by ibrutinib such as cancer, inflammatory diseases, and autoimmune diseases.